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ORIGINAL ARTICLE
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Abstract
N,N0-Bis[1-aryl-3-(piperidine-1-yl)propylidene]hydrazine dihydrochlorides were synthesized by
the reaction of 2 mols of 1-aryl-3-(piperidine-1-yl)-1-propanone hydrochlorides with 1 mol of
hydrazine hydrate. Aryl part was C6H5 (P1), 4-CH3C6H4 (P2), 4-CH3OC6H4 (P3), 4-HOC6H4 (P4),
4-ClC6H4 (P5), 3-CH3OC6H4 (P6), 4-FC6H4 (P7) and 4-BrC6H4 (P8). Except P1, all compounds were
reported for the first time. The chemical structures were confirmed by UV, 1H NMR, 13C NMR
and HRMS spectra. P1, P2, P7 and P8 against human hepatoma (Huh7) cells and P1, P2, P4, P5,
P6, P7 and P8 against breast cancer (T47D) cells have shown cytotoxicity. P1, P2 and P7 had
more potent cytotoxicity against Huh7 cells than the reference compound 5-FU, whereas only
P2 was more potent than the 5-FU against T47D cells. Representative compound P7 inhibited
the mitochondrial respiration at 144, 264 and 424 mM concentrations dose-dependantly in liver
homogenates. The results suggest that P1, P2, P7 and P8 may serve as model compounds for
further synthetic studies.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
neoplasm in the world and it ranks at third place in the list of
cancer-related mortality1,2. As HCC is usually asymptomatic in
the early stages, it is diagnozed at an advanced stage3,4.
Furthermore, for most patients with HCC, surgery is the only
curative treatment procedure, because HCC cells have high
resistance to chemotherapeutic agents, so treatment options of
HCC is very limited5. On the other hand, breast cancer is the
leading cause of cancer death among women with approximately
a million new cases each year6. Despite some therapy options
such as surgery, chemotherapy, endocrine and radiation therapy in
the treatment of breast cancer, several side effects and drug
resistance to chemotherapeutic agents are often encountered
problems in the course of therapy7. Therefore, it is necessary to
develop novel approaches and discover new drug candidates that
can be used in the treatment of HCC and/or breast cancer.
Mannich bases are synthesized by using a compound contain-
ing a reactive hydrogen atom, formaldehyde and a secondary
amine in general. This process is known as the Mannich reaction8.
They have various biological activities such as cytotoxic9–13,
anti-cancer8, anti-inflammatory14, anti-convulsant15 and anti-
fungal16,17 activities. Their cytotoxic activities may be attributed
to the a,b-unsaturated ketone, which is available in the chemical
structure of the compound or is produced by deamination process
in vivo or under simulated conditions in vitro18–20 or inhibition of
mitochondrial respiration21,22.
In the 1920s, Warburg et al.23 showed that tumour cells
produce large quantities of lactic acid from glucose via the
glycolytic pathway, even under aerobic conditions. It has been
proposed that this so-called ‘‘aerobic glycolysis’’ and the
consequent export of lactic acid leads to the low extracellular
pH (pHe) characteristic of solid tumours. More recent works
suggest that other metabolic pathways may also contribute to acid
production24,25. Alternatively, the pHe of solid tumours may be
independantly regulated in vivo because it is an intrinsic part of
the tumour phenotype26. A theoretical model has proposed that a
low pHe may confer survival and growth advantages for tumour
cells at the expense of the surrounding normal cells27 and in vitro
studies have shown that a low pHe favours metastatic behaviour
and production of angiogenic factors by human cells28,29. In any
case, as the intracellular pH (pHi) is tightly controlled and
maintained at neutral or slightly alkaline levels, the low pHe of
solid tumours leads to a pH gradient (pHe–pHi) across the plasma
membrane, which is the reverse of that found in normal tissue30.
This reverse or negative pH gradient (D pH) can also have import-
ant consequences for the effective delivery of chemotherapeutic
drugs from the blood stream to the tumour intracellular space31.
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A large D pH has been shown to be an important determinant
for tumour cell uptake of the anti-cancer drug 5-fluorouracil32,33,
and a low pHe favours cellular uptake of other chemotherapeutic
drugs that are weak acids, such as chlorambucil, or reduces uptake
of weak bases such as mitoxanthrone6,34,35.
The pH of tumours grown s.c. from 30 human tumour
xenograft lines in rats were analysed with the use of Hþ ion-
sensitive semi-microelectrodes prior to and following stimulation
of tumour cell glycolysis by intravenous infusion of glucose.
Without exception, all xenografts responded to the temporary
increase in plasma glucose concentration by an accumulation of
acidic metabolites, as indicated by a pH reduction to an average
value of 6.43 from 6.83. This pH value corresponds to a ten-fold
increase in Hþ ion activity in tumour tissues as compared to
arterial blood36. If this is the case, tumour-selective activation of
pH-sensitive anti-cancer agents, e.g. alkylating drugs, acid-labile
prodrugs or pH-sensitive immunoconjugates may thus be feasible
in a wide variety of human cancers.
Hydrazones are a special group of compounds in the Schiff
base family among condensation compounds which are synthe-
sized with aldehyde or ketones and amine derivatives in organic
chemistry. A great attention has been focused on hydrazones
for many researchers because of their various biological
activities such as anti-microbial, anti-fungal, anti-inflammatory
anti-tubercular, anti-convulsant, anti-tumoural and anti-viral
activities37.
Some polymeric micellar drug delivery systems having
hydrazone structure were developed for the delivery of doxorubi-
cin38. Hydrazone bond was included as it is cleavable under
biologically relevant conditions under slightly acidic conditions
(pH ca. 5, typical of the interstitial space of most solid tumours
and of the endosomal environment) and is relatively stable under
neutral conditions in blood plasma (pH 7.4)39,40. It was expected
that this should minimize the release of toxic-free doxorubicin
during delivery into tumour tissue and thus decrease side effects
and increase the range of doses exploitable in therapy. In another
study, the anti-cancer drug, adriamycin is conjugated to the core-
forming segments through the hydrazone linkers that are stable
under physiological conditions (pH 7.4), but cleavable under
acidic intracellular environments in endosomes and lysosomes
(pH 5–6)41.
Considering above mentioned problems and the logic explained,
the design and synthesis of hydrazones of some Mannich
bases, N,N0-bis[1-aryl-3-(piperidine-1-yl)propylidene]hydrazine
dihydrochlorides, were considered to develop new anti-cancer
drug candidates. These compounds were designed as
bi-functional alkylating agents and prodrug of Mannich bases,
which can provide a,b-unsaturated ketones responsible for the
cytotoxicity of them following hydrolysis of hydrazone in acidic
environment of cancer cells to produce 2 mols of mono
Mannich bases from 1 mol of hydrazone compound first. Then,
they undergo deamination to produce a,b-unsaturated ketones
which alkylate thiols. Another approach can be deamination of
hydrazone first and then reaction of the product generated with
cellular thiols by alkylation to produce cytototoxicity.
In addition, as it was previously shown that cytotoxic Mannich
bases derived from styryl ketones inhibit mitochondrial respir-
ation in rat liver cells21,22. Inhibition of mitochondrial respiratory
chain by the representative compound P7 was also tested in liver
homogenate to elucidate the possible mechanisms of actions of
the acid-sensitive hydrazones derived from mono Mannich bases.
Experimental
Chemistry
Melting points were determined on an Electrothermal 9100
melting point apparatus (IA9100, Electrothermal, Essex, UK). 1H
(400 MHz) and 13C (100 MHz) NMR spectra were recorded
employing a Varian 400 MHz FT spectrometer (Danbury, CT) for
hydrazone derivatives P1–P8, while 1H (60 MHz)-NMR spectra
were recorded on a Varian EM-360 spectrometer for precursor
mono Mannich bases P1m–P8m. NMR spectra of P1–P8 were
measured in MeOH-d4 solutions using tetra methyl silane as an
internal standard and chemical shifts are reported as parts per
million (d) while CDCl3 was used for P1m–P8m. Coupling
constants (J) are reported in Hertz. HRMS were recorded on a V6
Waters Micromass ZQ (Waters Corporation, Milford, MA) and
UV spectra were taken on a Thermo Electron Heios (a) (UVA
114903, Cambridge, UK) spectrophotometer for hydrazone
derivatives. Synthetic starting material, reagents and solvents
were purchased from Merck-Schuchardt (Hohenbrunn, Germany),
Riedel-de Haën (Seelze, Germany), J.T. Baker Chemical
Company (Phillipsburg, NJ), Fluka AG (Buchs, Switzerland),
Acros Organics Chemical Co. (Fair Lawn, NJ) and Sigma-Aldrich
Chemical Co. (St. Louis, MO).
General procedure for the synthesis of precursor mono Mannich
bases, 1-aryl-3-(piperidine-1-yl)-1-propanone hydrochlorides,
(P1m–P8m)
Except P2m, the mixture of corresponding acetophenone,
paraformaldehyde and piperidine hydrochloride in 1:1.5:1 mol
ratio was dissolved in ethanol. A few drops of HCl (37%) was
added into this mixture. Reaction content was refluxed for
sometime. Solvent was removed under vacuum. The residue
obtained was crystallized from suitable solvent. Crystals formed
were filtered, washed with diethyl ether, dried and crystallized.
The amount of suitable ketone (mmol), heating period (h),
melting point (C), crystallization solvent and yield (%) of the
compounds P1m–P8m (Scheme 1) were as follows: P1m
(20 mmol, 9 h, 191–194 C, methanol, 69%), P2m (8 mmol,
22 h, 182–187 C, methanol-ether, 25%), P3m (30 mmol, 4 h,
Scheme 1. Synthesis of N,N0-Bis[1-aryl-3-(piperidine-1-yl)propylidene]hydrazine dihydrochlorides, P1–P8. Reagents and conditions: (a)
paraformaldehyde, piperidine HCl, HCl (37%) and EtOH, 4–9 h, for P1m, P3m–P8m; acetic acid (99%), 22 h, for P2m; (b) Ethanolic acetic acid
(3% w/v), hydrazine hydrate for P1–P8. R1¼R2¼H (P1); R1¼CH3, R2¼H (P2); R1¼CH3O, R2¼H (P3); R1¼OH, R2¼H (P4); R1¼Cl, R2¼H
(P5); R1¼H, R2¼CH3O (P6); R1¼ F, R2¼H (P7); R1¼Br, R2¼H (P8).































215–218 C, ethanol, 32%), P4m (30 mmol, 4 h, 224–226 C,
ethanol, 33%), P5m (20 mmol, 9 h, 196–198 C, methanol-ether,
48%), P6m (30 mmol, 8 h, 152–155 C, ethanol-ether, 45%), P7m
(20 mmol, 8 h, 173–177 C, methanol, 21%), P8m (20 mmol, 8 h,
205–207 C, methanol, 41%). As precursor Mannich bases were
registered in literatures with their melting points42–45, NMR data
of them was not reported here. In the case of P2m, the mol ratio
of ketone, aldehyde and amine was 1:2:1. Acetic acid (99%,
30 ml) was used instead of ethanol. After refluxing 22 h, the
solvent was evoporated in vacuo and diethyl ether was added into
the residue and the mixture was cooled for one night at 4 C.
The precipitated compound was filtered, dried and crystallized
from methanol-diethyl ether.
General procedure for the synthesis of hydrazones, N,N0-bis[1-
aryl-3-(piperidine-1-yl)propylidene]hydrazine dihydrochlorides
(P1–P8)
A solution of hydrazine hydrate (1 mol ratio) in ethanol was
added to a solution of mono Mannich base (2 mol ratio) in
ethanolic acetic acid (3% w/v). The mixture was stirred at room
temperature for 17–26 h. The precipitated compound was
filtered, dried and crystallized from suitable solvent to give
the corresponding hydrazone derivatives. The crystals formed
were filtered and dried at room temperature. Experimental data
of P-series hydrazone compounds, P1–P8 (Scheme 1) are shown
in Table 1.
N,N0-bis[1-phenyl-3-(piperidine-1-yl)propylidene]hydrazine dihy-
drochlorides (P1). Yield: 57%. M.p. 185–189 C. UV MeOHmaks
(log ") 303 (4.22) nm. 1H NMR (MeOH-d4) d 1.80–1.95 (m,
12H), 2.97 (m, 8H), 3.54–3.63 (m, 8H), 7.51–7.56 (m, 8H), 8.03–
8.06 (m, 2H); 13C NMR (MeOH-d4) d 21.39, 23.05, 23.74, 53.15,
53.5, 127.39, 128.92, 131.09, 136.05, 163.27. HRMS: 431.32
(Mþ), 432.32 (Mþ 1)þ.
N,N0-bis[1-(4-methylphenyl)-3-(piperidine-1-yl)propylidene]
hydrazine dihydrochlorides (P2). Yield: 9%. M.p. 207–210 C.
UV MeOHmaks (log ") 313 (4.28) nm.
1H NMR (MeOH-d4) d 1.85 (m,
12H), 2.41 (s, 6H), 2.99 (m, 8H), 3.52–3.63 (m, 8H), 7.35 (d,
J¼ 7.7 Hz, 4H), 7.94 (t, J¼ 8.4 Hz, 4H); 13C NMR (MeOH-d4) d
20.23, 21.41, 23.05, 23.61, 53.14, 53.67, 127.36, 129.53, 133.33,
141.77, 163.08. HRMS 459.35 (Mþ), 460.35 (Mþ 1)þ.
N,N0-bis[1-(4-methoxyphenyl)-3-(piperidine-1-yl)propylidene]
hydrazine dihydrochlorides (P3). Yield: 72%. M.p. 214–217 C.
UV MeOHmaks (log ") 276 (4.38) nm.
1H NMR (MeOH-d4) d 1.85–
1.92 (m, 12H), 3.30 (m, 8H), 3.49–3.58 (m, 8H), 3.88 (s, 6H),
7.04 (d, J¼ 9.2 Hz, 4H), 8.03 (d, J¼ 8.8 Hz, 4H); 13C NMR
(MeOH-d4) d 21.43, 23.04, 32.38, 52.41, 53.59, 54.95, 113.86,
129.02, 130.51, 164.62, 195.17. HRMS 491.34 (Mþ), 492.34
(Mþ 1)þ.
N,N0-bis[1-(4-hydroxyphenyl)-3-(piperidine-1-yl)propylidene]
hydrazine dihydrochlorides (P4). Yield: 64%. M.p. 219–221 C.
UV MeOHmaks (log ") 281 (4.36) nm.
1H NMR (MeOH-d4) d 1.89 (m,
12H), 3.30 (m, 8H), 3.50–3.53 (m, 8H), 6.87 (d, J¼ 8.8 Hz, 4H),
7.94 (d, J¼ 8.8 Hz); 13C NMR (MeOH-d4) d 21.43, 23.04, 32.21,
52.48, 53.57, 115.22, 127.92, 130.75, 163.20, 195.07. HRMS
463.30 (Mþ).
N,N0-bis[1-(4-chlorophenyl)-3-(piperidine-1-yl)propylidene]
hydrazine dihydrochlorides (P5). Yield: 48%. M.p. 184–189 C.
UV MeOHmaks (log ") 254 (4.32), 311 (4.06) nm.
1H NMR (MeOH-
d4) d 1.57–1.93 (m, 12H), 3.04–3.15 (m, 8H), 3.51–3.63 (m, 8H),
7.55 (d, J¼ 7.7 Hz, 4H), 8.04 (d, J¼ 8.8 Hz, 4H); 13C NMR
(MeOH-d4) d 21.41, 23.06, 32.93, 52.15, 53.64, 128.96, 129.78,
134.7, 139.99, 195.5. HRMS 499.24 (Mþ), 501.24 (Mþ 2)þ.
N,N0-bis[1-(3-methoxyphenyl)-3-(piperidine-1-yl)propylidene]
hydrazine dihydrochlorides (P6). Yield: 88%. M.p. 187–192 C.
UV MeOHmaks (log ") 251 (3.94), 308 (3.67) nm.
1H NMR (MeOH-
d4) d 1.84 (m, 12H), 3.26 (m, 8H), 3.53–3.59 (m, 8H), 3.88 (s,
6H), 7.13 (dd, J¼ 8.3, 2.6 Hz, 2H), 7.46 (t, J¼ 8.1 Hz, 2H), 7.55
(t, J¼ 2.2 Hz, 2H), 7.58 (td, J¼ 7.7, 2.6 Hz); 13C NMR (MeOH-
d4) d 21.4, 23.03, 23.91, 53.19, 53.55, 54.96, 113.01, 116.38,
119.83, 130.1, 137.4, 160.44, 163.01; HRMS 491.34 (Mþ),
492.34 (Mþ 1)þ.
N,N0-bis[1-(4-fluorophenyl)-3-(piperidine-1-yl)propylidene]
hydrazine dihydrochlorides (P7). Yield: 12%. M.p. 204–209 C.
UV MeOHmaks (log ") 306 (4.30) nm.
1H NMR (MeOH-d4) d 1.80–
1.86 (m, 12H), 2.99 (m, 8H), 3.52–3.60 (m, 8H), 7.27 (t,
J¼ 8.8 Hz, 4H), 8.11 (d, J¼ 8.8 Hz, 4H); 13C NMR (MeOH-d4) d
21.42, 23.05, 23.72, 53.18, 53.4, 115.91, 129.9, 132.37, 163.61,
166.11. HRMS 467.3 (Mþ), 468.3 (Mþ 1)þ.
N,N0-bis[1-(4-bromophenyl)-3-(piperidine-1-yl)propylidene]
hydrazine dihydrochlorides (P8). Yield: 14%. M.p. 195–199 C.
UV MeOHmaks (log ") 263 (4.13), 313 (4.30) nm.
1H NMR (MeOH-
d4) d 1.84–2.01 (m, 12H), 3.03 (m, 8H), 3.50–3.61 (m, 8H), 7.72
(d, J¼ 8.8 Hz, 4H), 7.96 (d, J¼ 8.8 Hz, 4H); 13C NMR (MeOH-
d4) d 21.39, 23.04, 32.84, 52.12, 53.66, 128.67, 129.82, 132.03,
135.04, 195.71. HRMS 587.14 (Mþ), 589.14 (Mþ 2)þ, 591.14
(Mþ 4)þ.
Cytotoxic activity assay
Hydrazone compounds, P1–P8 and 5-FU, which was used as
positive control compound, were tested against human hepatoma
(Huh7) and breast cancer (T47D) cells by NCI-60
SulforhodamineB Assay46,47 to identify the compounds with
growth-inhibitory activity. Briefly, T47D and Huh7 cells (5000 or
10 000) were inoculated into 96-well plates in 100 ml of standard
DMEM medium (Gibco-Invitrogen Corp., Grand Island, NY) 24 h
Table 1. Experimental data of P series hydrazone compounds, P1–P8 (Scheme 1).
Compound Formula MW Reaction time (h) Crystallization solvent Yield (%) Melting point (C)
P1 C28H40Cl2N4 502.26 17 Ethanol 57 185–189*
P2 C30H44Cl2N4 530.29 23 Ethanol 9 208–210
P3 C30H44Cl2N4O2 562.28 18 Methanol 72 214–217
P4 C28H40Cl2N4O2 534.25 18 Ethanol 64 219–221
P5 C28H38Cl4N4 570.19 18 Ethanol 48 186–189
P6 C30H44Cl2N4O2 562.28 26 Chloroform 88 190–192
P7 C28H38Cl2F2N4 538.24 26 Chloroform/methanol 12 204–209
P8 C28H38Br2Cl2N4 658.08 20 Ethyl acetate/methanol 14 195–199
*Reported melting point of P1 was 172.5–175 C52.































prior to treatment with the compounds in increasing concentra-
tions (2.5, 5, 10, 20, 40 mM). After 72 h of treatment, the cell
culture medium was discarded and the cells were washed with 1
PBS (CaCl2-, MgCl2-free) (Gibco, Invitrogen). Then cells were
fixed by gentle addition of 50 ml of ice-cold 10% (w/v) trichloro-
acetic acid (MERCK) for 60 min at 4 C. After fixation, cells were
washed with distilled water and dried in air. The cells were
stained using 50 ml of a 0.4% (m/v) of sulforhodamine (Sigma-
Aldrich) in 1% acetic acid solution at room temperature for
10 min. Extra unbound dye was washed five times with 200ml of
1% acetic acid and air-dried. Sulforhodamine stain, which was
bound to cellular proteins, was then solubilized by adding 200ml
of 10 mM Tris-base solution and the absorbance was acquired at
515 nm. Absorbance values of the compounds were normalized to
their corresponding controls (DMSO). The IC50 values were
calculated as previously described48. The IC50 values reported are
the average of two independent determinations which differed by
510%.
Inhibition of mitochondrial respiration assay
Animals
Experiments were performed on nine adult male Wistar rats (8-
week-old), housed in a thermo-neutral environment (22 2 C),
on a 12:12 h photoperiod, and provided food and water ad libitum.
This investigation was carried out in accordance with the Guide
for the Care and Use of Laboratory published by the US National
Institute of Health and approved by the institutional animal care
commitee (NIH publication No. 85-23, revised 1996). Animals
were submitted to a general anaesthesia with isoflurane and the
liver was excised and immediately used for the study of
mitochondrial respiration.
Study of mitochondrial respiration
Isolation of liver mitochondria. All operations were carried out at
4 C. Liver was finely minced in ice-cold isolation buffer (50 mM
Tris, 1 mM EGTA, 70 mM Sucrose, 210 mM Mannitol, pH 7.4 at
4 C) and then homogenized with a Potter–Elvehjem device. The
homogenate was centrifuged at 1300g for 3 min at 4 C. The
supernatant was centrifuged at 10 000 g for 10 min at 4 C to
sediment mitochondria. Finally, the mitochondrial pellet was
washed twice and then suspended in 50 mM Tris, 70 mM Sucrose,
210 mM Mannitol, pH 7.4 at 4 C. Protein content was routinely
assayed with a Bradford assay using bovine serum albumin (BSA)
as a standard49. Mitochondria were kept on ice until use.
Measurement of the mitochondrial respiratory chain
complexes. Mitochondrial respiration was measured using a
Clark-type electrode (Strathkelvin Instruments, Glasgow, UK) as
previously reported50. Before oxygraph measurement, 3 ml of
solution M (100 mM KCl, 50 mM Mops, 1 mM EGTA, 5 mM Kpi,
1 mg/ml BSA) was added to the oxygraph chambers for 10 min
then, 0.15 mg of isolated liver mitochondria were introduced
with 10 mM glutamate and 2.5 mM malate and the temperature
was maintained at 25 C. After that, succinate (25 mM) and
adenosine diphosphate were added. Mitochondrial respiration in
these conditions allowed determining the activities of the
complexes I, II, III and IV (Figure 2). After that, the represen-
tative Fluor-bearing compound P7 was added at different
concentrations.
Results are expressed as meanSEM. Statistical analyses
were performed using one-way ANOVA followed by a
Newman–Keuls post-test. (GraphPad Prism 5, Graph Pad
Software, Inc., San Diego, CA). Statistical significance required
a p50.05.
Results
In this study, hydrazone compounds P1–P8 bearing a piperidine
moiety were synthesized as presented in Scheme 1 for the first
time, except compound P1. Experimental data of P-series of
compounds are presented in Table 1. Compounds were obtained
with the yield of 9–88%. The chemical structures of newly
synthesized compounds were assigned on the basis of their
spectroscopic data such as UV, 1H NMR and 13C NMR and
HRMS. Spectral data are presented at the experimental section.
Spectral data of the compounds were in accordance with the
chemical structures of the compounds synthesized.
All the synthesized compounds having the chemical structure
of N,N0-bis[1-aryl-3-(piperidine-1-yl)propylidene]hydrazine dihy-
drochlorides were evaluated against the human hepatoma cells
(Huh7) and breast cancer cells (T47D) in terms of cytotoxic
activity. The cytotoxicity of the compounds and reference
compound 5-FU are listed in Table 2 in terms of the inhibitory
potencies (IC50, mM).
Hydrazone compounds, P1 (4.86 times), P2 (10.08 times), P7
(5.26 times) and P8 (1.07 times, almost equal to 5-FU) had higher
cytotoxic potency than the reference compound, 5-FU, against
Huh7 cells. Of the compounds synthesized, only P2, a 4-methyl
derivative, had more potent cytotoxic activity than 5-FU against
T47D cells (1.45 times). The representative cytotoxic compound
P7 inhibited the mitochondrial respiration significantly at 144,

















Concentraon (μM) of P7
Figure 1. In vitro effects of increasing concentrations of P7 on rat liver
mitochondrial respiratory chain. p50.05 (one-way ANOVA followed
by Tukey).
Table 2. Cytotoxic activity of hydrazones P1–P8











5-FU, 5-Fluorouracil; *, no inhibition.
































In this study, hydrazone compounds were designed as acid-
sensitive compounds targeting cancer cells that have lower pH
value than corresponding normal tissues. There are three
suggested mechanisms of action for the cytotoxicity of designed
chemical structures51,52: firstly, hydrazone compounds may
undergo deamination to produce N,N0-bis(1-aryl-
propylidene)hydrazine, then interact with cellular thiol to form
cytotoxicity. Secondly, hydrazone compound undergoes hydroly-
sis at the acidic pH of cancer cells to produce 2 mols of mono
Mannich bases (Pm-Series) from 1 mol of hydrazone (P-Series)
first, then they may undergo deamination to produce biologically
active species a,b-unsaturated ketones, which alkylate cellular
thiols to produce cytotoxicity. Thirdly, inhibition of mitochondrial
respiration by the compounds.
The chemical structures of newly synthesized compounds were
assigned on the basis of their spectroscopic data such as UV, 1H
NMR and 13C NMR and HRMS. Spectral data are presented in
the experimental section. Spectral data of the compounds were in
accordance with the chemical structures of the compounds
synthesized. As an example, compound P1’s spectral data can
be summarized. When examined, the 1H NMR spectrum of P1,
the protons on the phenyl ring in the molecule were observed as 2-
hydrogen-multiplet and 8-hydrogen-multiplet in d 8.03–8.06 ppm
and d 7.51–7.56 ppm, respectively. The protons belonged to
ethylene chain between nitrogen atom of piperidine ring and
carbon atom of imine group gave 8-hydrogen multiplet in d
3.54–3.63 ppm. The protons of methylene group next to the
nitrogen atom in piperidine ring were observed in d 2.97 ppm as
8-hydrogen multiplet. The other protons of piperidine ring gave
12-hydrogen multiplet in d 1.80–1.95 ppm. In 13C NMR
spectrum, the carbon signal belonged to the imine group,
which has shown that expected structure had synthesized, was
observed in d 163.27 ppm and it was the most important signal
of the spectrum. The signal observed in d 136.05 ppm belonged
to carbons of phenyl ring next to the imine group. The signals of
other protons of phenyl ring was in d 131.09 ppm, d 128.92 ppm
and d 127.39 ppm. The carbon atoms of methylene group next to
nitrogen atom in piperidine ring gave signals of d 53.50 ppm.
The carbon atoms of ethylene chain next to nitrogen atom of
piperidine ring was observed at d 53.15 ppm, while the signal of
carbon atoms in the same ring next to the imine group was in
d 23.74 ppm. The carbon atoms on the position 4 according to
the nitrogen atom of piperidine ring gave signal in d 23.05 ppm.
In the spectrum, the signal observed in d 21.39 ppm belonged to
the carbon atoms which were on positions 3 and 5 according to
the nitrogen atom of piperidine ring. In HRMS spectrum of
compound P1, molecular ion signal which confirmed the
structure of P1 was observed in m/z 431.32. Mþ 1 signal was
in m/z 432.32. The signal that had the highest rate of relative
abundance and confirmed that the fragmentation of the molecule
occured between the imine groups was in m/z 216.16. In UV
spectrum of compound P1, the signal which was observed in
303 nm belonged to the chromophor imine group-conjugated
phenyl ring. This signal was due to !  electronic transition
of imine group.
When the relationships between the cytotoxicity of the
compounds and physicochemical parameters tested (Hammett ,
Hansch  and log P, data not shown) were investigated, there were
no correlation. Data were analysed by using the bivariate, Pearson
correlation method in SPSS for Windows program (IBM, New
York, NY). Observed cytotoxicities with P-Series of compounds
against cell lines used, may be explained with the optimum
deamination ratio of the compounds in cancer cells tested to
produce biologically active alkylation centre or interaction with
some steps at the electron transport chain in mitochondria. On the
other hand, absence of cytotoxicity with some compounds of P-
Series may be explained by faster deamination of the compounds
than the optimal level in the tested cells, which can cause faster
elimination of the active metabolite before reaching their target.
Second explanation for the absence of cytotoxicity may be the
lack of interaction with the proper receptors for the bioactivity or
the production of 1-aryl-3-(3-aryl-4,5-dihydropyrazol-1-yl)pro-
pan-1-one, which does not have suitable centre for thiol
alkylation. Third, the compounds which dont have cytotoxicity
may not have any interaction with electron transport chain in
mitochondria.
Previously, it was shown that cytotoxic Mannich bases derived
from styryl ketones inhibit mitochondrial respiration in rat liver
cells21,22. Accordingly, inhibition of mitochondrial respiratory
chain by the compound P7 in this study suggests that inhibition of
mitochondrial respiration may be one of the contributing mech-
anisms to the cytotoxic activity of P7 and the other cytotoxic
compounds.
Conclusions
In conclusion, new hydrazones synthesized having a piperidine
moiety as potential anti-cancer candidate deserved further struc-
tural modification and pharmacological evaluation. We reported
here the compounds P2–P8 for the first time with their synthesis,
spectral analysis and cytotoxicities of the P-series of compounds
against Huh7 and T47D cell lines. Compounds P1 (4.86 times),
P2 (10.08 times), P7 (5.26 times) and P8 (1.07 times, almost
equal to 5-FU), against Huh7 cell line, compound P2 (1.45 times)
against T47D cell line may serve as model candidate compounds
for further synthetic designs and studies. Inhibition of the
mitochondrial respiration by the representative compound P7
suggests that it may be one of the contributing mechanisms to the
cytotoxic activity of the hydrozones.
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Figure 2. Schematic representation of the mitochondrial respiratory chain
with specific substrates and inhibitors (modified from a previous
study53). CI, complex I; CII, complex II; CIII, complex III; CIV,
complex IV; TMPD, N,N,N0,N0-tetramethyl-p-phenylenediamine dihy-
drochloride; H, proton.
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